ImprimisRx to Focus on Investments in Quality at the 2019 American Academy of Ophthalmology Meeting
October 08 2019 - 7:30AM
ImprimisRx, the nation’s leading ophthalmic-focused outsourcing
facility and pharmaceutical compounding business, a wholly-owned
subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced
its participation at the upcoming 2019 American Academy of
Ophthalmology (AAO) Annual Meeting to be held at the Moscone Center
in San Francisco, CA, October 12-15. The American Academy of
Ophthalmology is the world’s largest association of eye physicians
and surgeons, encompassing a community of 32,000 medical doctors.
More than 90 percent of practicing ophthalmologists are AAO
members. The annual meeting includes a global community of
innovators in the art and science of ophthalmology in addition to
game-changing research, techniques, and technologies.
As part of ImprimisRx’s commitment to quality
manufacturing, the company will be discussing its ongoing
investments in cGMP (Current Good Manufacturing Practices). cGMP
standards (21 C.F.R. Parts 210 and 211) are the highest federal
drug manufacturing standards. As an FDA-registered and
FDA-inspected outsourcing facility, ImprimisRx has made and
continues to make significant investments in equipment, processes
and personnel to comply with these standards. ImprimisRx’s cGMP
compliance program is designed to ensure ImprimisRx’s status as the
leading ophthalmic-focused outsourcing facility and pharmaceutical
compounding business in the United States.
Please click here to view a video discussing
cGMP quality processes undertaken to date in ImprimisRx’s
manufacturing facilities.
John Saharek, President of ImprimisRx,
commented, “The need for our formulations has never been greater.
With nearly 3.5 million sterile doses dispensed to date and over
6,000 ophthalmic healthcare professionals prescribing our
formulations, we see demand continuing to grow as we expand our
unique suite of offerings. This year has been a record-breaker and
2020 is likely going be another year of record-breaking growth.
Producing products at the highest federal quality standards in our
facilities, which are all inspected by the US Food and Drug
Administration (FDA), is what our customers expect; and it is what
they will get as we ensure access to affordable medications for
individuals with needs not adequately met by FDA-approved
products.”
At the conference, attendees will have the
opportunity to meet with ImprimisRx representatives at Exhibit
#7601 in the Moscone Center West Hall to learn about ImprimisRx’s
full portfolio of formulations, including several new topical and
injectable formulations to further expand the ImprimisRx portfolio
of ophthalmic-focused, acute care compounded medications which help
address unique patient needs.
About ImprimisRx
ImprimisRx is the nation’s leading
ophthalmology-focused outsourcing facility and pharmaceutical
compounding business, serving thousands of ophthalmologists and
optometrists in all 50 states, with 40 proprietary ophthalmic
formulations. ImprimisRx is headquartered in San Diego, CA and owns
two FDA-inspected production and dispensing facilities in
Ledgewood, New Jersey. There have been over one million eyes served
by the formulations produced at these facilities.
About Harrow Health
Harrow Health, Inc. (NASDAQ: HROW) owns a
portfolio of healthcare businesses, including ImprimisRx, the
nation’s leading ophthalmology outsourcing facility and
pharmaceutical compounding business. The company holds large
equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals,
Melt Pharmaceuticals, Mayfield Pharmaceuticals, Stowe
Pharmaceuticals and Radley Pharmaceuticals, all companies founded
as subsidiaries of Harrow Health. The Company also owns
royalty rights in certain drug candidates being developed by
Surface, Melt, Mayfield and Radley. Harrow intends to create,
invest in and grow paradigm shifting healthcare businesses that put
patients first. For more information about Harrow Health,
please visit the Investor Relations section of the corporate
website by clicking here.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Any statements in this release that
are not historical facts may be considered such "forward-looking
statements." Forward-looking statements are based on management's
current expectations and are subject to risks and uncertainties
which may cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include our ability to make commercially available our
compounded formulations and technologies in a timely manner or at
all; physician interest in prescribing our formulations; risks
related to our compounding pharmacy operations; our ability to
enter into other strategic alliances, including arrangements with
pharmacies, physicians and healthcare organizations for the
development and distribution of our formulations; our ability to
obtain intellectual property protection for our assets; our ability
to accurately estimate our expenses and cash burn, and raise
additional funds when necessary; risks related to research and
development activities; the projected size of the potential market
for our technologies and formulations; unexpected new data, safety
and technical issues; regulatory and market developments impacting
compounding pharmacies, outsourcing facilities and the
pharmaceutical industry; competition; and market conditions. These
and additional risks and uncertainties are more fully described in
Harrow Health’s filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Such documents may be read free of
charge on the SEC's web site at www.sec.gov. Undue reliance should
not be placed on forward-looking statements, which speak only as of
the date they are made. Except as required by law, Harrow Health
undertakes no obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
No ImprimisRx compounded formulation is
FDA-approved. Other than drugs compounded at a registered
outsourcing facility, all ImprimisRx compounded formulations
require a prescription for an individually identified patient
consistent with federal and state laws.
Investor Contact:Jon
Pattonjpatton@harrowinc.com 858-704-4587
Media Contact:Deb HollidayHolliday
Communications, Inc.deb@hollidaycommunications.net412-877-4519
Source: Harrow Health, Inc.
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Apr 2024 to May 2024
Harrow (NASDAQ:HROW)
Historical Stock Chart
From May 2023 to May 2024